Targeting MMP-9 in Diabetic Foot Ulcers

Cooper, 2002, The biology of the skin, J. R. Soc. Med., 95, 109, 10.1177/014107680209500221

Dinh, 2012, Mechanisms involved in the development and healing of diabetic foot ulceration, Diabetes, 61, 2937, 10.2337/db12-0227

Christian, 2006, Stress and Wound Healing, Neuroimmunomodulation, 13, 337, 10.1159/000104862

Nijm, 2007, Impaired cortisol response to acute stressors in patients with coronary disease. Implications for inflammatory activity, J. Intern. Med., 262, 375, 10.1111/j.1365-2796.2007.01817.x

Ebrecht, 2004, Perceived stress and cortisol levels predict speed of wound healing in healthy male adults, Psychoneuroendocrinology, 29, 798, 10.1016/S0306-4530(03)00144-6

Kometani, 2017, Cortisol overproduction results from DNA methylation of CYP11B1 in hypercortisolemia, Sci. Rep., 7, 11205, 10.1038/s41598-017-11435-2

Vileikyte, 2018, Cortisol Synthesis Enzyme CYP11B1 as Tissue Biomarker for Diabetic Foot Ulcers, Diabetes, 67, 641-P, 10.2337/db18-641-P

Szymanowski, 2011, Elevated levels of circulating matrix metalloproteinase-9 are associated with a dysregulated cortisol rhythm—A case-control study of coronary artery disease, Psychoneuroendocrinology, 36, 139, 10.1016/j.psyneuen.2010.06.012

Yen, 2011, Prostaglandin E2 Induces Matrix Metalloproteinase 9 Expression in Dendritic Cells through Two Independent Signaling Pathways Leading to Activator Protein 1 (AP-1) Activation, J. Biol. Chem., 286, 38913, 10.1074/jbc.M111.252932

Lazaro, 2016, Elevated levels of matrix metalloproteinases and chronic wound healing: An updated review of clinical evidence, J. Wound Care, 25, 277, 10.12968/jowc.2016.25.5.277

Gross, 1962, Collagenolytic activity in amphibian tissues: A tissue culture assay, Proc. Natl. Acad. Sci. USA, 48, 1014, 10.1073/pnas.48.6.1014

Puente, 2003, Human and mouse proteases: A comparative genomic approach, Nat. Rev. Genet., 4, 544, 10.1038/nrg1111

Alexandrescu, V.A. (2016). Roles of matrix metalloproteinases in cutaneous wound healing. Wound Healing—New Insights into Ancient Challenges, IntechOpen.

Springman, 1990, Multiple modes of activation of latent human fibroblast collagenase: Evidence for the role of a Cys73 active-site zinc complex in latency and a “cysteine switch” mechanism for activation, Proc. Natl. Acad. Sci. USA, 87, 364, 10.1073/pnas.87.1.364

Bannikov, 2002, Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide, J. Biol. Chem., 277, 16022, 10.1074/jbc.M110931200

Okamoto, 2001, Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation, J. Biol. Chem., 276, 29596, 10.1074/jbc.M102417200

1989, Human fibroblast collagenase-alpha-macroglobulin interactions. Localization of cleavage sites in the bait regions of five mammalian alpha-macroglobulins, J. Biol. Chem., 264, 393

Baker, 2002, Metalloproteinase inhibitors: Biological actions and therapeutic opportunities, J. Cell Sci., 115, 3719, 10.1242/jcs.00063

McCawley, 2000, Matrix metalloproteinases: Multifunctional contributors to tumor progression, Mol. Med. Today, 6, 149, 10.1016/S1357-4310(00)01686-5

DeClerck, 1994, Protease inhibitors: Role and potential therapeutic use in human cancer, Eur. J. Cancer, 30, 2170, 10.1016/0959-8049(94)00460-M

Whittaker, 1999, Design and therapeutic application of matrix metalloproteinase inhibitors, Chem. Rev., 99, 2735, 10.1021/cr9804543

Coussens, 2002, Matrix metalloproteinase inhibitors and cancer—trials and tribulations, Science, 295, 2387, 10.1126/science.1067100

Winberg, 2013, Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets, Tumor Biol., 34, 2041, 10.1007/s13277-013-0842-8

Vandenbroucke, 2014, Is there new hope for therapeutic matrix metalloproteinase inhibition?, Nat. Rev. Drug Discov., 13, 904, 10.1038/nrd4390

Fingleton, 2008, MMPs as therapeutic targets—Still a viable option?, Semin. Cell Dev. Biol., 19, 61, 10.1016/j.semcdb.2007.06.006

Martin, 2007, The other side of MMPs: Protective roles in tumor progression, Cancer Metastasis Rev., 26, 717, 10.1007/s10555-007-9089-4

Wynn, 1999, Latest FDA approvals for dentistry, Gen. Dent., 47, 19

Yang, 2015, Matrix metalloproteinases as therapeutic targets for stroke, Brain Res., 1623, 30, 10.1016/j.brainres.2015.04.024

Brea, 2009, Reorganization of the cerebral vasculature following ischaemia, Rev. Neurol., 49, 0645

Yang, 2009, Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia, Neuroscience, 158, 983, 10.1016/j.neuroscience.2008.06.025

Krishnaswamy, 2017, Matrix metalloproteinases: The sculptors of chronic cutaneous wounds, Biochim. Biophys. Acta, 1864, 2220, 10.1016/j.bbamcr.2017.08.003

Rayment, 2009, Finding the culprit: A review of the influences of proteases on the chronic wound environment, Int. J. Low. Extrem. Wounds, 8, 19, 10.1177/1534734609331596

Trengove, 1999, Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors, Wound Repair Regen., 7, 442, 10.1046/j.1524-475X.1999.00442.x

Frykberg, 2015, Challenges in the treatment of chronic wounds, Adv. Wound Care, 4, 560, 10.1089/wound.2015.0635

Rice, 2013, Burden of diabetic foot ulcers for medicare and private insurers, Diabetes Care, 37, 651, 10.2337/dc13-2176

Wagner, 1981, The dysvascular foot: A system for diagnosis and treatment, Foot Ankle Int., 2, 64, 10.1177/107110078100200202

Fortington, 2013, Short and long term mortality rates after a lower limb amputation, Eur. J. Vasc. Endovasc. Surg., 46, 124, 10.1016/j.ejvs.2013.03.024

McLennan, 2006, Molecular aspects of wound healing in diabetes, Prim. Intent., 14, 8

Ambrozova, 2017, Models for the study of skin wound healing. The role of Nrf2 and NF-kappaB, Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub., 161, 1, 10.5507/bp.2016.063

Caley, 2015, Metalloproteinases and wound healing, Adv. Wound Care, 4, 225, 10.1089/wound.2014.0581

Agren, 2001, Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds, Exp. Dermatol., 10, 337, 10.1034/j.1600-0625.2001.100506.x

Hariono, 2018, Matrix metalloproteinase 9 (MMP9) in wound healing of diabetic foot ulcer: Molecular target and structure-based drug design, Wound Med., 22, 1, 10.1016/j.wndm.2018.05.003

Greene, 2006, Microdeformational wound therapy: Effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients, Ann. Plast. Surg., 56, 418, 10.1097/01.sap.0000202831.43294.02

Heule, 2008, The role of topical negative pressure in wound repair: Expression of biochemical markers in wound fluid during wound healing, Wound Repair Regen., 16, 488, 10.1111/j.1524-475X.2008.00395.x

Xu, 2017, Mesenchymal stem cells correct impaired diabetic wound healing by decreasing ECM proteolysis, Physiol. Genom., 49, 541, 10.1152/physiolgenomics.00090.2016

Yang, 2017, Inhibition of methylglyoxal-induced AGEs/RAGE expression contributes to dermal protection by N-acetyl-L-cysteine, Cell. Physiol. Biochem., 41, 742, 10.1159/000458734

Tsang, 2017, A pilot randomized, controlled study of nanocrystalline silver, Manuka honey, and conventional dressing in healing diabetic foot ulcer, Evid.-Based Complement. Altern. Med., 2017, 15, 10.1155/2017/5294890

Nguyen, 2018, Validation of matrix metalloproteinase-9 (MMP-9) as a novel target for treatment of diabetic foot ulcers in humans and discovery of a potent and selective small-molecule MMP-9 inhibitor that accelerates healing, J. Med. Chem., 61, 8825, 10.1021/acs.jmedchem.8b01005

Nguyen, 2018, Expression of active matrix metalloproteinase-9 as a likely contributor to the clinical failure of aclerastide in treatment of diabetic foot ulcers, Eur. J. Pharmacol., 834, 77, 10.1016/j.ejphar.2018.07.014

Fleischmann, 1993, Vacuum sealing as treatment of soft tissue damage in open fractures, Unfallchirurg, 96, 488

Armstrong, 2005, Negative pressure wound therapy after partial diabetic foot amputation: A multicentre, randomised controlled trial, Lancet, 366, 1704, 10.1016/S0140-6736(05)67695-7

Vuerstaek, 2006, State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.) with modern wound dressings, J. Vasc. Surg., 44, 1029, 10.1016/j.jvs.2006.07.030

Badillo, 2007, Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhances wound closure, Cell Tissue Res., 329, 301, 10.1007/s00441-007-0417-3

Wu, 2007, Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis, Stem Cells, 25, 2648, 10.1634/stemcells.2007-0226

Kucharzewski, 2019, Novel trends in application of stem cells in skin wound healing, Eur. J. Pharmacol., 843, 307, 10.1016/j.ejphar.2018.12.012

Leavitt, 2016, Stem cells and chronic wound healing: State of the art, Chronic Wound Care Manag. Res., 3, 7

Javazon, 2007, Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bone marrow stromal progenitor cells, Wound Repair Regen., 15, 350, 10.1111/j.1524-475X.2007.00237.x

Chen, 2015, Mesenchymal stem cell-laden anti-inflammatory hydrogel enhances diabetic wound healing, Sci. Rep., 5, 18104, 10.1038/srep18104

Mokhtari, 2017, A review on various uses of N-acetyl cysteine, Cell J., 19, 11

Khan, 2004, Administration of N-acetylcysteine after focal cerebral ischemia protects brain and reduces inflammation in a rat model of experimental stroke, J. Neurosci. Res., 76, 519, 10.1002/jnr.20087

Singh, 2014, Advanced glycation end products and diabetic complications, Korean J. Physiol. Pharmacol., 18, 1, 10.4196/kjpp.2014.18.1.1

Aktunc, 2010, N-acetyl cysteine promotes angiogenesis and clearance of free oxygen radicals, thus improving wound healing in an alloxan-induced diabetic mouse model of incisional wound, Clin. Exp. Dermatol., 35, 902, 10.1111/j.1365-2230.2010.03823.x

Singh, 2001, Advanced glycation end-products: A review, Diabetologia, 44, 129, 10.1007/s001250051591

Martí-Carvajal, A.J., Gluud, C., Nicola, S., Simancas-Racines, D., Reveiz, L., Oliva, P., and Cedeño-Taborda, J. (2015). Growth factors for treating diabetic foot ulcers. Cochrane Database Syst. Rev., CD005848.

Ziyadeh, 2011, A matched cohort study of the risk of cancer in users of becaplermin, Adv. Skin Wound Care, 24, 31, 10.1097/01.ASW.0000392922.30229.b3

Alexi, 2015, Platelet-derived growth factor-D modulates extracellular matrix homeostasis and remodeling through TIMP-1 induction and attenuation of MMP-2 and MMP-9 gelatinase activities, Biochem. Biophys. Res. Commun., 457, 307, 10.1016/j.bbrc.2014.12.106

Gooyit, 2014, A chemical biological strategy to facilitate diabetic wound healing, ACS Chem. Biol., 9, 105, 10.1021/cb4005468

Vukelic, 2014, Angiotensin II, from vasoconstrictor to growth factor, Circ. Res., 114, 754, 10.1161/CIRCRESAHA.114.303045

Yahata, 2006, A novel function of Angiotensin II in skin wound healing: Induction of fibroblast and keratinocyte migration by angiotensin ii via heparin-binding epidermal growth factor (egf)-like growth factor-mediated egf receptor transactivation, J. Biol. Chem., 281, 13209, 10.1074/jbc.M509771200

Chang, 2016, Restructuring of the extracellular matrix in diabetic wounds and healing: A perspective, Pharmacol. Res., 107, 243, 10.1016/j.phrs.2016.03.008

Rodgers, 2003, Acceleration of healing, reduction of fibrotic scar, and normalization of tissue architecture by an angiotensin analogue, NorLeu3-A(1-7), Plast. Reconstr. Surg., 111, 1195, 10.1097/01.PRS.0000047403.23105.66

Balingit, 2012, NorLeu3-A(1–7) stimulation of diabetic foot ulcer healing: Results of a randomized, parallel-group, double-blind, placebo-controlled phase 2 clinical trial, Wound Repair Regen., 20, 482, 10.1111/j.1524-475X.2012.00804.x

Guo, 2008, Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells, Regul. Pept., 147, 37, 10.1016/j.regpep.2007.12.005

Liu, 2009, Increased matrix metalloproteinase-9 predicts poor wound healing in diabetic foot ulcers, Diabetes Care, 32, 117, 10.2337/dc08-0763

Rayment, 2008, Increased matrix metalloproteinase-9 (MMP-9) activity observed in chronic wound fluid is related to the clinical severity of the ulcer, Br. J. Dermatol., 158, 951, 10.1111/j.1365-2133.2008.08462.x

Clark, I.M. (2010). Mechanism-based profiling of MMPs. Matrix Metalloproteinase Protocols, Humana Press.

Meisel, 2017, Selective small-molecule inhibitors as chemical tools to define the roles of matrix metalloproteinases in disease, Biochim. Biophys. Acta, 1864, 2001, 10.1016/j.bbamcr.2017.04.011

Vidova, 2017, A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition, Anal. Chim. Acta, 964, 7, 10.1016/j.aca.2017.01.059

Saghatelian, 2004, Activity-based probes for the proteomic profiling of metalloproteases, Proc. Natl. Acad. Sci. USA, 101, 10000, 10.1073/pnas.0402784101

Freije, 2003, Activity-based enrichment of matrix metalloproteinases using reversible inhibitors as affinity ligands, J. Chromatogr., 1009, 155, 10.1016/S0021-9673(03)00920-8

Hesek, 2006, Synthesis of an inhibitor-tethered resin for detection of active matrix metalloproteinases involved in disease, J. Org. Chem., 71, 5848, 10.1021/jo060058h

Brown, 2000, Potent and selective mechanism-based inhibition of gelatinases, J. Am. Chem. Soc., 122, 6799, 10.1021/ja001461n

Gooyit, M.D. (2013). Gelatinase Inhibition as a Therapeutic Approach for Treatment of Diseases of Matrix, University of Notre Dame.

Forbes, 2009, Active site ring-opening of a thiirane moiety and picomolar inhibition of gelatinases, Chem. Biol. Drug Des., 74, 527, 10.1111/j.1747-0285.2009.00881.x

Testero, 2011, Sulfonate-containing thiiranes as selective gelatinase inhibitors, ACS Med. Chem. Lett., 2, 177, 10.1021/ml100254e

Gao, 2015, Acceleration of diabetic wound healing using a novel protease–anti-protease combination therapy, Proc. Natl. Acad. Sci. USA, 112, 15226, 10.1073/pnas.1517847112

Gooyit, 2011, Selective water-soluble gelatinase inhibitor prodrugs, J. Med. Chem., 54, 6676, 10.1021/jm200566e

Tamarat, 2002, Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways, Lab. Investig., 82, 747, 10.1097/01.LAB.0000017372.76297.EB

Inada, 2007, Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8), FASEB J., 21, 2580, 10.1096/fj.06-7860com

Smiell, 1999, Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: A combined analysis of four randomized studies, Wound Repair Regen., 7, 335, 10.1046/j.1524-475X.1999.00335.x

Overall, 2006, Towards third generation matrix metalloproteinase inhibitors for cancer therapy, Br. J. Cancer, 94, 941, 10.1038/sj.bjc.6603043

Amar, 2017, Clinical implications of compounds designed to inhibit ECM-modifying metalloproteinases, Proteomics, 17, 1600389, 10.1002/pmic.201600389

Levin, 2017, Next generation matrix metalloproteinase inhibitors—Novel strategies bring new prospects, Biochim. Biophys. Acta, 1864, 1927, 10.1016/j.bbamcr.2017.06.009

Appleby, 2017, Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9, J. Biol. Chem., 292, 6810, 10.1074/jbc.M116.760579

Bendell, 2015, Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors, J. Clin. Oncol., 33, 4030, 10.1200/jco.2015.33.15_suppl.4030

Shah, 2018, Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: Results from a phase I study, Clin. Cancer Res., 24, 3829, 10.1158/1078-0432.CCR-17-2469

Kikkeri, 2011, Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential, Nat. Med., 18, 143

Hu, 2004, Inhibitors of gelatinase B/matrix metalloproteinase-9 activity: Comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody, Biochem. Pharmacol., 67, 1001, 10.1016/j.bcp.2003.10.030

Paemen, 1995, Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-Site ELISA and inhibition of enzymatic activity, Eur. J. Biochem., 234, 759, 10.1111/j.1432-1033.1995.759_a.x

Vowden, 2014, Wound dressings: Principles and practice, Surgery, 32, 462

Rayment, 2008, Attenuation of protease activity in chronic wound fluid with bisphosphonate-functionalised hydrogels, Biomaterials, 29, 1785, 10.1016/j.biomaterials.2007.12.043

Tronci, 2016, Protease-sensitive atelocollagen hydrogels promote healing in a diabetic wound model, J. Mater. Chem. B, 4, 7249, 10.1039/C6TB02268E

Jeong, 2016, Technological development of structural DNA/RNA-based RNAi systems and their applications, Adv. Drug Deliv. Rev., 104, 29, 10.1016/j.addr.2015.10.008

Wang, 2010, Delivery of siRNA therapeutics: Barriers and carriers, AAPS J., 12, 492, 10.1208/s12248-010-9210-4

Georgiou, 2004, Nanoscopic cationic methacrylate star homopolymers:  synthesis by group transfer polymerization, characterization and evaluation as transfection reagents, Biomacromolecules, 5, 2221, 10.1021/bm049755e

Srinivasachari, 2008, Polycationic β-cyclodextrin “Click Clusters”:  Monodisperse and versatile scaffolds for nucleic acid delivery, J. Am. Chem. Soc., 130, 4618, 10.1021/ja074597v

Xu, 2009, Star-shaped cationic polymers by atom transfer radical polymerization from β-cyclodextrin cores for nonviral gene delivery, Biomacromolecules, 10, 285, 10.1021/bm8010165

Cryan, 2004, Cell transfection with polycationic cyclodextrin vectors, Eur. J. Pharm. Sci., 21, 625, 10.1016/j.ejps.2004.01.001

Yang, 2009, Dynamic changes in matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 levels during wound healing in diabetic rats, J. Am. Podiatr. Med. Assoc., 99, 489, 10.7547/0990489

Li, 2014, Cationic star-shaped polymer as an siRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats, Int. J. Nanomed., 9, 3377, 10.2147/IJN.S66368

Li, 2017, Efficiency and safety of β-CD-(D3)7 as siRNA carrier for decreasing matrix metalloproteinase-9 expression and improving wound healing in diabetic rats, ACS Appl. Mater. Interfaces, 9, 17417, 10.1021/acsami.7b02809

Wang, 2018, MicroRNA-129 and -335 promote diabetic wound healing by inhibiting Sp1-Mediated MMP-9 expression, Diabetes, 67, 1627, 10.2337/db17-1238